comparemela.com

Latest Breaking News On - Garvin yang - Page 1 : comparemela.com

CEPI's founding CEO to lead Wellcome—Chutes & Ladders

CEPI's founding CEO to lead Wellcome—Chutes & Ladders
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Baan
Nordland
Norway
California
United-states
Garvin-yang
Jon-garfield
Annette-matthies
Neil-mcfarlane
Bruce-harmon
Eli-lilly
Lee-swem

Pheon Therapeutics Appoints Oncology Expert Arvin Yang, MD, PhD as Chief Medical Officer

Pheon Therapeutics Appoints Oncology Expert Arvin Yang, MD, PhD as Chief Medical Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Cambridge
Cambridgeshire
United-kingdom
London
City-of
Garvin-yang
Memorial-sloan-kettering-cancer-center
Rutgers-robert-wood-johnson-medical-school
Harvard-medical-school
Bristol-myers-squibb
Research-corporation-technologies
Atlas-venture

Mersana Therapeutics Announces Topline Data from UPLIFT

UPLIFT clinical trial did not meet its primary endpoint Company realigns focus and significantly reduces expenses to extend cash runway into 2026Conference.

Cambridge
Cambridgeshire
United-kingdom
Jason-fredette
Garvin-yang
Anna-protopapas
Mersana-therapeutics-inc
Exchange-commission
Nasdaq
Positive-population
Senior-vice-president
Chief-medical-officer

Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization

Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Cambridge
Cambridgeshire
United-kingdom
Jason-fredette
Garvin-yang
Anna-protopapas
Exchange-commission
Mersana-therapeutics-inc
Nasdaq
Mersana-therapeutics
Positive-population
Senior-vice-president

Upifitamab Rilsodotin Fails to Meet ORR End Point in NaPi2b+ Platinum-Resistant Ovarian Cancer

The phase 1/2 UPLIFT trial evaluating the antibody-drug conjugate upifitamab rilsodotin in patients with platinum-resistant ovarian cancer failed to meet its primary end point of investigator-assessed overall response rate in the NaPi2b-positive population.

Garvin-yang
Mersana-therapeutics
Ovarian-cancer
News
Nct03319628
Antibody-drug-conjugate
Upifitamab
Rilsodotin
Xmt-1536

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.